Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
77.29
-0.33 (-0.43%)
At close: Jun 26, 2026, 4:00 PM EDT
76.92
-0.37 (-0.47%)
After-hours: Jun 26, 2026, 7:00 PM EDT

Company Description

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions.

The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.

The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications.

In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions.

Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions.

It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Haemonetics Corporation
Haemonetics logo
Country United States
Founded 1971
IPO Date May 9, 1991
Industry Medical Devices
Sector Healthcare
Employees 3,009
CEO Christopher Simon

Contact Details

Address:
125 Summer Street
Boston, Massachusetts 02110
United States
Phone 781 848 7100
Website haemonetics.com

Stock Details

Ticker Symbol HAE
Exchange NYSE
Stock Type Common Stock
Fiscal Year April - March
Reporting Currency USD
CIK Code 0000313143
CUSIP Number 405024100
ISIN Number US4050241003
Employer ID 04-2882273
SIC Code 3841

Key Executives

Name Position
Christopher A. Simon Chief Executive Officer, President and Director
Michelle L. Basil Esq., J.D. Executive Vice President, General Counsel and Secretary
Roy Galvin Executive Vice President and Chief Commercial Officer
Frank W. Chan Ph.D. Executive Vice President and Chief Operating Officer
Farris Maryanne E. Maunsell Vice President, Chief Accounting Officer and Principal Accounting Officer
Olga Guyette Senior Director of Investor Relations
Rajeev Varma Senior Vice President of Strategy and Corporate Development
Laurie A. Miller Senior Vice President and Chief Human Resources Officer
Dr. Jan Hartmann M.D. Senior Vice President and Chief Medical Officer
David J. Wilson President of Plasma Business Unit

Latest SEC Filings

Date Type Title
Jun 9, 2026 ARS Filing
Jun 9, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 9, 2026 DEF 14A Other definitive proxy statements
Jun 5, 2026 8-K Current Report
May 28, 2026 SD Form - SD
May 20, 2026 10-K Annual Report
May 13, 2026 SCHEDULE 13G/A Filing
May 7, 2026 8-K Current Report
May 1, 2026 8-K Current Report
Apr 30, 2026 SCHEDULE 13G Filing